DNA Tests
Product Search & Filter
Showing 121 – 140 out of 173
Page 7 out of 9
| Tick | Thumbnails | Products | Price | Quantity | Action |
|---|---|---|---|---|---|
 |
Oncomine Acute Myeloid Leukemia (AML) Panel – Targeted NGS Solution for AML Research The Oncomine Acute Myeloid Leukaemia (AML) Panel is a targeted next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of AML. It enables simultaneous detection of key mutations, gene fusions, and copy number variations across clinically relevant genes associated with AML. |
5.500,00 د.إ | |||
 |
5.500,00 د.إ | ||||
|
5.500,00 د.إ | ||||
|
Oncomine Comprehensive myeloid/ Leukemia Panel (DNA + RNA fusions) The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes. |
5.500,00 د.إ | |||
|
5.500,00 د.إ | ||||
 |
Oncomine MDS Panel – Comprehensive Genetic Testing for Myelodysplastic Syndromes The Oncomine Myelodysplastic Syndrome (MDS) Panel detects genetic mutations linked to MDS and blood cancers. Accurate, next-generation sequencing. Book your test today. |
5.500,00 د.إ | |||
|
5.500,00 د.إ | ||||
|
4.100,00 د.إ | ||||
|
Oncomine Myeloproliferative Neoplasm (MPN) Panel – Accurate NGS Testing for MPN Mutations The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a targeted next-generation sequencing (NGS) assay designed for the comprehensive detection of key driver mutations in myeloproliferative neoplasms. It enables the simultaneous analysis of JAK2, CALR, and MPL genes, which are critical for MPN diagnosis and classification. The panel offers high sensitivity, detecting low-frequency variants with as little as 10 ng of input RNA or DNA, making it ideal for limited or degraded samples. |
5.500,00 د.إ | |||
 |
Oncotype DX Breast Cancer Test – Personalized Risk Assessment & Treatment Guidance The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation. |
35.000,00 د.إ | |||
 |
OneOme® RightMed® comprehensive test Sample Type : Buccal Swab
Methodology : PCR
TAT : 14 Days |
3.500,00 د.إ | |||
|
Osteoporosis Gene (PCR) Sample Type : Whole Blood
Methodology : Real-time PCR
TAT : 15 Days |
1.500,00 د.إ | |||
|
1.520,00 د.إ | ||||
 |
Panorama Basic ( Natera Prenatal screening ) Get the Panorama Basic NIPT in Dubai from 10 weeks. Screen for Down syndrome, trisomies & microdeletions with 99% accuracy. Non-invasive blood test. Results in 7-10 days. Book now!Sample Type : Maternal bloodMethodology : PCR-single nucleotide polymorphism (SNP)-based technologyTAT : 7-10 Days |
3.750,00 د.إ | |||
|
Panorama Extended Prenatal Screening by Natera – Advanced Non-Invasive Genetic Test Panorama Extended Prenatal Screening is a cutting-edge, non-invasive prenatal test (NIPT) designed to provide expectant parents with critical insights into their baby’s health.Sample Type : Maternal bloodMethodology : PCR-single nucleotide polymorphism (SNP)-based technologyTAT : 10 Days |
4.500,00 د.إ | |||
|
Panorama Twin( Natera Pre Natal Screening) Sample Type : Maternal blood
Methodology : PCR-single nucleotide polymorphism (SNP)-based technology
TAT : 10 Days |
3.500,00 د.إ | |||
 |
PCR FOR HLA B27 (EDTA) PCR for HLA-B27 (EDTA) is a molecular diagnostic test used to detect the HLA-B27 gene, which is strongly associated with autoimmune disorders like ankylosing spondylitis and other spondyloarthropathies. Utilizing Polymerase Chain Reaction (PCR) technology, this test offers high sensitivity and specificity, ensuring accurate and reliable results. |
2.400,00 د.إ | |||
|
PD-L1 (22C3) Dako CPS IHC Test – Accurate Immunohistochemistry for Cancer Diagnosis The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment. |
3.500,00 د.إ | |||
|
3.200,00 د.إ | ||||
|
PredictLife Test – Advanced DNA Health & Wellness Analysis for Personalized Insights PredictLife Test is a cutting-edge DNA-based health and longevity assessment that provides personalized insights into your genetic predispositions, lifestyle risks, and potential health outcomes. Using advanced AI and genomic analysis, it evaluates factors like disease risks, aging patterns, nutrition, and fitness optimization. |
3.200,00 د.إ |
